PHVS deucrictibant XR cuts HAE attack rates 83% in CHAPTER-3
PHVS reports phase III CHAPTER-3 results for deucrictibant XR: 83% reduction in HAE attack rates versus placebo and nearly half of treated patients remained attack-free over 24 weeks. The drug was well-tolerated with quality-of-life gains.
The phase III CHAPTER-3 study showed deucrictibant XR achieved an 83% reduction in HAE attack rates versus placebo, with nearly half of treated patients remaining attack-free over 24 weeks. The drug was well-tolerated, improved quality of life, and offers injectable-like efficacy in an oral formula…